Moonlake Immunotherapeutics · NASDAQ:MLTX

Bodenstedt Matthias sold 87,795 Moonlake Immunotherapeutics shares (Form 4)

Traded Apr 9 to Apr 10, 2026 · Filed Apr 10, 2026

From Apr 9 to Apr 10, 2026, Bodenstedt Matthias (Chief Financial Officer) sold 87,795 Moonlake Immunotherapeutics shares at an average US$18.95 for US$1.66M under a trading plan, leaving 1,188,510 shares. Filed Apr 10, 2026 (Form 4).

Sold
87,795 shares
Price
US$18.95 average (US$18.94 to US$19.51)
Value
US$1.66M
Holding after
1,188,510 shares
Trading plan
Yes (Made under a plan set in advance)
Role
Chief Financial Officer

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
Apr 9, 2026Class A ordinary shares, par value $0.0001 per shareSale85,870US$18.941,190,435Direct
Apr 10, 2026Class A ordinary shares, par value $0.0001 per shareSale1,925US$19.511,188,510Direct

Source

View original at SEC

Related